B12 CAR T cells

B12 CAR T cells are an experimental adoptive cell therapy consisting of T cells engineered to express a chimeric antigen receptor (CAR) derived from the B12 nanobody clone. This therapy specifically targets B7-H3 (CD276), a cell surface glycoprotein that is highly overexpressed in various solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and neuroblastoma, while showing limited expression in normal tissues. Developed by researchers at the National Institutes of Health (NIH), the B12 CAR utilizes a camelid-derived single-domain antibody (VHH) or nanobody as its antigen-binding domain, which offers potential advantages in terms of size and stability compared to traditional scFv-based CARs. In preclinical studies, B12 CAR T cells demonstrated potent cytolytic activity against B7-H3-positive tumor cells in vitro and significant antitumor efficacy in metastatic PDAC and neuroblastoma mouse models without significant toxicity.

Other names

B12 nanobody-based CAR T cellsB-12 nanobody-based CAR T cellsB 12 nanobody-based CAR T cellsB7-H3-targeted B12 CAR T cellsB-7-H3-targeted B12 CAR T cellsB 7-H3-targeted B12 CAR T cells